HC Wainwright Brokers Boost Earnings Estimates for VYGR

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Equities researchers at HC Wainwright upped their Q1 2025 earnings per share (EPS) estimates for Voyager Therapeutics in a research note issued to investors on Thursday, March 13th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.21) per share for the quarter, up from their previous forecast of ($0.30). HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Voyager Therapeutics’ Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.86) EPS, FY2026 earnings at ($1.04) EPS, FY2027 earnings at ($1.07) EPS, FY2028 earnings at ($1.47) EPS and FY2029 earnings at ($1.40) EPS.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The company had revenue of $4.39 million for the quarter, compared to analysts’ expectations of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter in the previous year, the company posted $1.25 EPS.

VYGR has been the topic of several other reports. Citigroup started coverage on shares of Voyager Therapeutics in a report on Monday, December 2nd. They set a “buy” rating and a $12.00 price target on the stock. Wells Fargo & Company set a $10.00 price target on Voyager Therapeutics and gave the stock an “overweight” rating in a report on Wednesday. StockNews.com cut Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Canaccord Genuity Group reduced their target price on Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Voyager Therapeutics currently has an average rating of “Buy” and an average price target of $14.86.

Voyager Therapeutics Trading Down 4.2 %

Shares of VYGR opened at $3.90 on Monday. The company’s fifty day simple moving average is $4.83 and its 200-day simple moving average is $5.82. The company has a market cap of $213.04 million, a P/E ratio of 5.49 and a beta of 0.99. Voyager Therapeutics has a twelve month low of $3.56 and a twelve month high of $10.66.

Insider Transactions at Voyager Therapeutics

In related news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the sale, the chief operating officer now directly owns 112,328 shares in the company, valued at $634,653.20. This represents a 5.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. In the last quarter, insiders sold 10,778 shares of company stock valued at $58,548. Company insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Voyager Therapeutics by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 3,215,441 shares of the company’s stock valued at $18,232,000 after buying an additional 29,014 shares in the last quarter. Farallon Capital Management LLC boosted its stake in Voyager Therapeutics by 12.2% in the fourth quarter. Farallon Capital Management LLC now owns 2,570,700 shares of the company’s stock valued at $14,576,000 after acquiring an additional 278,700 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Voyager Therapeutics by 24.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,380,615 shares of the company’s stock worth $7,828,000 after purchasing an additional 275,571 shares during the last quarter. Vestal Point Capital LP increased its position in shares of Voyager Therapeutics by 151.0% during the fourth quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company’s stock worth $6,974,000 after purchasing an additional 740,000 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Voyager Therapeutics by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 1,084,238 shares of the company’s stock valued at $6,149,000 after purchasing an additional 4,729 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.